Eiger BioPharmaceuticals' Asset Sale

Eiger BioPharmaceuticals raised a round of funding on June 29, 2017. Investors include Theragene Pharmaceuticals.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical NCEs fr…

Articles about Eiger BioPharmaceuticals' Asset Sale: